David A. Siegel Design Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 108,500 shares of DSGN stock, worth $635,810. This represents 0.0% of its overall portfolio holdings.
Number of Shares
108,500
Previous 146,700
26.04%
Holding current value
$635,810
Previous $566,000
35.51%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding DSGN
# of Institutions
96Shares Held
33.6MCall Options Held
13KPut Options Held
0-
Sr One Capital Management, LP6.53MShares$38.2 Million7.89% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$24.7 Million1.83% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$13.5 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$11.4 Million0.35% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.81MShares$10.6 Million0.01% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $327M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...